Company intelligence / Profile preview

RANA Development

Cambridge, Massachusetts, United Statesranaprocess.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

RaNA Therapeutics developed a proprietary platform for selectively activating gene expression by targeting long non-coding RNAs. Lead programs targeted rare genetic disorders such as spinal muscular atrophy and Friedreich’s ataxia. The company advanced preclinical candidates toward IND-enabling studies before rebranding as Translate Bio and expanding into mRNA therapeutics, including clinical-stage vaccine development.

Therapeutic areas: Rare DiseasesNeurologyInfectious Diseases
Modalities: RNA therapymRNA-based drugsOligonucleotide therapy
Industry: Biotech

Partnerships

Sanofi Pasteur

Beyond the preview

Go deeper on RANA Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RANA Development.

Explore the full profile